280 related articles for article (PubMed ID: 32485363)
1. Antisense oligonucleotide-based therapies for the treatment of osteoarthritis: Opportunities and roadblocks.
Nakamura A; Ali SA; Kapoor M
Bone; 2020 Sep; 138():115461. PubMed ID: 32485363
[TBL] [Abstract][Full Text] [Related]
2. microRNA-181a-5p antisense oligonucleotides attenuate osteoarthritis in facet and knee joints.
Nakamura A; Rampersaud YR; Nakamura S; Sharma A; Zeng F; Rossomacha E; Ali SA; Krawetz R; Haroon N; Perruccio AV; Mahomed NN; Gandhi R; Rockel JS; Kapoor M
Ann Rheum Dis; 2019 Jan; 78(1):111-121. PubMed ID: 30287418
[TBL] [Abstract][Full Text] [Related]
3. Antisense oligonucleotide therapeutics in neurodegenerative diseases: the case of polyglutamine disorders.
Silva AC; Lobo DD; Martins IM; Lopes SM; Henriques C; Duarte SP; Dodart JC; Nobre RJ; Pereira de Almeida L
Brain; 2020 Feb; 143(2):407-429. PubMed ID: 31738395
[TBL] [Abstract][Full Text] [Related]
4. Translating Antisense Technology into a Treatment for Huntington's Disease.
Lane RM; Smith A; Baumann T; Gleichmann M; Norris D; Bennett CF; Kordasiewicz H
Methods Mol Biol; 2018; 1780():497-523. PubMed ID: 29856033
[TBL] [Abstract][Full Text] [Related]
5. Phospholamban Inhibition by a Single Dose of Locked Nucleic Acid Antisense Oligonucleotide Improves Cardiac Contractility in Pressure Overload-Induced Systolic Dysfunction in Mice.
Morihara H; Yamamoto T; Oiwa H; Tonegawa K; Tsuchiyama D; Kawakatsu I; Obana M; Maeda M; Mohri T; Obika S; Fujio Y; Nakayama H
J Cardiovasc Pharmacol Ther; 2017 May; 22(3):273-282. PubMed ID: 27811197
[TBL] [Abstract][Full Text] [Related]
6. Current Status of Antisense Oligonucleotide-Based Therapy in Neuromuscular Disorders.
Bizot F; Vulin A; Goyenvalle A
Drugs; 2020 Sep; 80(14):1397-1415. PubMed ID: 32696107
[TBL] [Abstract][Full Text] [Related]
7. Drug Discovery Perspectives of Antisense Oligonucleotides.
Kim Y
Biomol Ther (Seoul); 2023 May; 31(3):241-252. PubMed ID: 36859811
[TBL] [Abstract][Full Text] [Related]
8. The intratracheal administration of locked nucleic acid containing antisense oligonucleotides induced gene silencing and an immune-stimulatory effect in the murine lung.
Uemura Y; Hagiwara K; Kobayashi K
PLoS One; 2017; 12(11):e0187286. PubMed ID: 29107995
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligonucleotide targeting CD39 improves anti-tumor T cell immunity.
Kashyap AS; Thelemann T; Klar R; Kallert SM; Festag J; Buchi M; Hinterwimmer L; Schell M; Michel S; Jaschinski F; Zippelius A
J Immunother Cancer; 2019 Mar; 7(1):67. PubMed ID: 30871609
[TBL] [Abstract][Full Text] [Related]
10. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
[TBL] [Abstract][Full Text] [Related]
11. In Vivo Administration of Therapeutic Antisense Oligonucleotides.
Statello L; Ali MM; Kanduri C
Methods Mol Biol; 2021; 2254():273-282. PubMed ID: 33326082
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of bovine milk extracellular vesicles for the delivery of locked nucleic acid antisense oligonucleotides.
Grossen P; Portmann M; Koller E; Duschmalé M; Minz T; Sewing S; Pandya NJ; van Geijtenbeek SK; Ducret A; Kusznir EA; Huber S; Berrera M; Lauer ME; Ringler P; Nordbo B; Jensen ML; Sladojevich F; Jagasia R; Alex R; Gamboni R; Keller M
Eur J Pharm Biopharm; 2021 Jan; 158():198-210. PubMed ID: 33248268
[TBL] [Abstract][Full Text] [Related]
13. Disarmed anthrax toxin delivers antisense oligonucleotides and siRNA with high efficiency and low toxicity.
Dyer PDR; Shepherd TR; Gollings AS; Shorter SA; Gorringe-Pattrick MAM; Tang CK; Cattoz BN; Baillie L; Griffiths PC; Richardson SCW
J Control Release; 2015 Dec; 220(Pt A):316-328. PubMed ID: 26546271
[TBL] [Abstract][Full Text] [Related]
14. MicroRNA-34a-5p Promotes Joint Destruction During Osteoarthritis.
Endisha H; Datta P; Sharma A; Nakamura S; Rossomacha E; Younan C; Ali SA; Tavallaee G; Lively S; Potla P; Shestopaloff K; Rockel JS; Krawetz R; Mahomed NN; Jurisica I; Gandhi R; Kapoor M
Arthritis Rheumatol; 2021 Mar; 73(3):426-439. PubMed ID: 33034147
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the effect of 2'-O-methyl, fluoro hexitol, bicyclo and Morpholino nucleic acid modifications on potency of GalNAc conjugated antisense oligonucleotides in mice.
Prakash TP; Yu J; Kinberger GA; Low A; Jackson M; Rigo F; Swayze EE; Seth PP
Bioorg Med Chem Lett; 2018 Dec; 28(23-24):3774-3779. PubMed ID: 30342955
[TBL] [Abstract][Full Text] [Related]
16. Quantitative fluorescence imaging determines the absolute number of locked nucleic acid oligonucleotides needed for suppression of target gene expression.
Buntz A; Killian T; Schmid D; Seul H; Brinkmann U; Ravn J; Lindholm M; Knoetgen H; Haucke V; Mundigl O
Nucleic Acids Res; 2019 Jan; 47(2):953-969. PubMed ID: 30462278
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotides: the next frontier for treatment of neurological disorders.
Rinaldi C; Wood MJA
Nat Rev Neurol; 2018 Jan; 14(1):9-21. PubMed ID: 29192260
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic antisense oligonucleotides for movement disorders.
Doxakis E
Med Res Rev; 2021 Sep; 41(5):2656-2688. PubMed ID: 32656818
[TBL] [Abstract][Full Text] [Related]
19. Biomaterial strategies for improved intra-articular drug delivery.
Mancipe Castro LM; García AJ; Guldberg RE
J Biomed Mater Res A; 2021 Apr; 109(4):426-436. PubMed ID: 32780515
[TBL] [Abstract][Full Text] [Related]
20. Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development.
Dhuri K; Bechtold C; Quijano E; Pham H; Gupta A; Vikram A; Bahal R
J Clin Med; 2020 Jun; 9(6):. PubMed ID: 32604776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
